This Calgary-based micro cap medical device sales company has announced the launch of its first product solution aimed at solving the testing problems airlines and airport terminal operators face as they work to make air travel safe for domestic and international travel.
FluroTech Ltd. (TSX-V:TEST) has claimed that the FluroTest air travel solution is a COVID testing platform that the company anticipates will be capable of running 3,000 tests per hour directly at the point of collection with accurate results immediately available to every passenger within five minutes, according to the release.
For those who have attempted to travel during the pandemic, destinations that require a negative test have proved to be difficult for travelers lining up a test before departure. This potential breakthrough might alleviate the majority of concern and difficulties that accompany air travel in this era.
Traders seemed to agree that this was exciting news, as they grabbed up shares to $0.165/share (+3.13%) in early trade. As cases around the globe seem to be piling up, any evolution of testing and detecting technologies can be a huge asset to society.
